tradingkey.logo
tradingkey.logo
Search

Shionogi & Co Ltd - FDA Accepts Shionogi's Ensitrelvir NDA For Review As First Oral Therapy For Prevention Of Covid-19 Following Exposure

ReutersSep 3, 2025 12:01 AM
facebooktwitterlinkedin

- Shionogi & Co Ltd 4507.T:

  • SHIONOGI & CO LTD: FDA ACCEPTS SHIONOGI'S ENSITRELVIR NDA FOR REVIEW AS FIRST ORAL THERAPY FOR PREVENTION OF COVID-19 FOLLOWING EXPOSURE

  • SHIONOGI & CO LTD: FDA HAS SET AN ACTION DATE OF JUNE 16, 2026 UNDER PRESCRIPTION DRUG USER FEE ACT (PDUFA)

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Recommended Articles

Tradingkey
KeyAI